Powell C Bethan, Kenley Eric, Chen Lee-May, Crawford Beth, McLennan Jane, Zaloudek Charles, Komaromy Miriam, Beattie Mary, Ziegler John
Gynecologic Oncology Program and Cancer Risk Program, University of California San Francisco Comprehensive Cancer Center, 2340 Sutter Street, Room N424, San Francisco, CA 94143, USA.
J Clin Oncol. 2005 Jan 1;23(1):127-32. doi: 10.1200/JCO.2005.04.109.
Women who carry deleterious mutations of BRCA1 or BRCA2 genes have up to a 54% lifetime risk of developing ovarian cancer. After childbearing, women at high risk increasingly choose bilateral risk-reducing salpingo-oophorectomy (RRSO). Two recent studies of BRCA mutation carriers reported occult malignancy in 2.5% of women undergoing RRSO. This study aimed to increase this detection rate using a protocol.
In 1996, the University of California San Francisco Gynecologic Oncology Program instituted a surgical-pathologic RRSO protocol that was composed of complete removal and serial sectioning of both ovaries and fallopian tubes, peritoneal and omental biopsies, and collection of peritoneal washings for cytology. We report the pathologic findings in 67 BRCA mutation carriers according to the degree of adherence to this protocol.
Of the 67 procedures, the protocol was followed completely or partially in 41 (61%). Seven occult malignancies were discovered, four in the fallopian tube and three in the ovaries. Six of these were microscopic, and all seven (17%) were found in specimens from complete or partial protocol procedures as opposed to standard procedures (P = .026). Other variables such as age, parity, BRCA1 or BRCA2 mutation, or type of surgery did not alter the strong effect of protocol procedure on the cancer detection rate.
A rigorous operative and pathologic protocol for RRSO increases the detection rate of occult ovarian malignancy in BRCA mutation carriers nearly seven-fold. If confirmed, this finding will alter postoperative management because additional staging, chemotherapy, and follow-up may be necessary in affected women.
携带BRCA1或BRCA2基因有害突变的女性患卵巢癌的终生风险高达54%。生育后,高危女性越来越多地选择双侧降低风险的输卵管卵巢切除术(RRSO)。最近两项针对BRCA突变携带者的研究报告称,在接受RRSO的女性中,隐匿性恶性肿瘤的发生率为2.5%。本研究旨在通过一种方案提高这种检测率。
1996年,加利福尼亚大学旧金山分校妇科肿瘤项目制定了一项手术病理RRSO方案,该方案包括完整切除双侧卵巢和输卵管并进行连续切片、腹膜和网膜活检以及收集腹膜冲洗液进行细胞学检查。我们根据对该方案的遵守程度报告了67名BRCA突变携带者的病理结果。
在67例手术中,41例(61%)完全或部分遵循了该方案。发现了7例隐匿性恶性肿瘤,4例在输卵管,3例在卵巢。其中6例为显微镜下可见,所有7例(17%)均在完全或部分遵循方案的手术标本中发现,而非标准手术标本(P = 0.026)。其他变量,如年龄、产次、BRCA1或BRCA2突变或手术类型,均未改变方案手术对癌症检测率的显著影响。
RRSO的严格手术和病理方案可使BRCA突变携带者隐匿性卵巢恶性肿瘤的检测率提高近7倍。如果得到证实,这一发现将改变术后管理,因为受影响的女性可能需要额外的分期、化疗和随访。